Saturday 17 October 2026
Export STLN’s income statement to Excel — free account
Starling Oncology, Inc.
STLN Healthcare Medical Care Facilities
Starling Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.7 million, up 27.8% from fiscal 2024. In the quarter to June 2026, revenue grew 34.6%, EPS grew 46.7%, free cash flow grew 196.7% and total debt rose 6.46%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
6.43
0.48
−6.95%
Follow STLN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 4 | 4 | 4 |
+8 more TTM periods Free account |
| 214.12% | 775.91% | 999.19% | (4,132.17%) | ||
| (21.47%) | (26.19%) | (35.93%) | (38.67%) | ||
ROIC |
(117.66%) | (63.75%) | (80.21%) | (70.85%) | |
Return on Tangible Assets |
(81.31%) | (90.26%) | (115.51%) | (120.02%) | |
Average Days of Receivables |
41.46 | 39.76 | 43.07 | 47.48 | |
Free Cash Flow per Share |
(0.03) | (0.25) | (0.30) | (0.28) | |
Free Cash Flow |
(3.29) | (25.73) | (27.79) | (27.53) | |
Capital Expenditures |
(3.61) | (3.91) | (3.20) | (3.89) | |
| Other line items | |||||
Cash ROIC |
(3.42%) | (27.78%) | (29.17%) | (30.06%) | |
Accounts Receivable Turnover |
9.58 | 10.00 | 9.31 | 8.03 | |
Accounts Payable Turnover |
10.40 | 12.04 | 12.63 | 13.05 | |
Inventory Turnover |
27.66 | 25.32 | 31.68 | 27.10 | |
Average Days of Payables |
44.44 | 37.54 | 36.96 | 33.12 | |
Days of Inventory on Hand |
14.75 | 19.14 | 14.45 | 17.55 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
18.98% | 19.86% | 21.00% | 22.21% | |
Share Based Compensation of Revenue |
0.87% | 0.88% | 0.91% | 0.98% | |
Interest Coverage |
(3.42) | (4.28) | (3.20) | (3.90) | |
Operating CF/Net income |
(0.01) | 0.50 | 0.41 | 0.36 | |
Depreciation/Fixed assets |
1.10 | 1.07 | 1.43 | 1.47 | |
Capex/Depreciation |
(0.31) | (0.34) | (0.21) | (0.25) | |
Revenue per Share |
5.70 | 5.36 | 5.44 | 4.73 | |
Operating CF per Share |
0.00 | (0.21) | (0.27) | (0.24) | |
Capex per Share |
(0.04) | (0.04) | (0.03) | (0.04) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 |
Columns are period end dates